Media
Featured Content
20-Jan-2012
CHMP recommends EU approval to update Novartis drug Glivec® label to include three year treatment for GIST patients after surgery
"This CHMP positive opinion marks another major milestone in the evolution of GIST treatment, which began almost a decade ago with the introduction of Glivec in the metastatic setting," said Hervé Hoppenot, President, Novartis Oncology.
08-Dec-2011
New data confirms Novartis drug Afinitor® significantly extends time women with advanced breast cancer live without tumor growth
"These data provide longer-term evidence of the benefit of adding everolimus to hormonal therapy in patients whose disease progressed while on or following initial hormonal treatment, representing a major paradigm shift in the management of ER+HER2- breast cancer," said Gabriel Hortobagyi, MD, Chair of Breast Medical Oncology, University of Texas MD Anderson Cancer Center and lead study author. "Everolimus is the first treatment to enhance the efficacy of hormonal therapy in this patient population, where there remains a significant unmet need."
Click on the titles below to view the complete Novartis Oncology abstracts that will be part of ASCO's 2010 Annual Meeting.
5-Jun-2010
2:00 p.m. CDT - Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT)
4:00 p.m. CDT - Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS)
View Materials Related to Products:
Research
Novartis Oncology is at the forefront of the discovery of new and better therapies. Explore our active pipeline and the many ways in which we strive to improve and extend patient lives.
SEARCH OUR WEBSITES
CONTACT
For information about Novartis Oncology, please contact:
novartis.com
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.